| INTRODUC TI ON
Despite advances in the treatment of haemophilia A in the past decades, 1 current standard approaches continue to require frequent and time-consuming intravenous infusions of factor VIII (FVIII) concentrates. [1] [2] [3] Up to 20% of persons with haemophilia A (PwHA) develop alloantibodies (inhibitors) to FVIII treatments, typically within the first 10-15 days of treatment. 4, 5 Inhibitors are classified as low titre (<5 Bethesda units [BU]/mL) or high titre (>5 BU/mL at least once) based on the highest documented inhibitor level and the occurrence of an anamnestic response after re-exposure to factor concentrate. 6 Among PwHA with inhibitors, therapeutic options have been more limited, particularly burdensome and suboptimally effective. [7] [8] [9] [10] [11] [12] Current guidelines recommend immune tolerance induction (ITI) to eliminate high-titre inhibitors as first-line treatment in these individuals, which can enable effective replacement therapy and make prophylaxis feasible in order to prevent or lessen the negative impact of persistent inhibitors on patients' morbidity and quality of life. [13] [14] [15] [16] [17] [18] However, ITI is associated with high costs, involves frequent, prolonged infusions and is not always effective. 19, 20 Bleeding in PwHA with inhibitors requires bypassing agents (BPAs; ie, activated prothrombin complex concentrates, recombinant factor VIIa).
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Until recently, the only prophylaxis regimens for PwHA with inhibitors with acceptable outcomes required intravenous infusions of BPAs every other day, with dosing regimens varying from three times a week to daily in clinical practice. [10] [11] [12] 21 Despite BPA prophylaxis, PwHA with inhibitors have significant breakthrough bleeding, 10, 12 and often experience poor health-related quality of life (HRQoL), increased health care costs, joint pain and other orthopaedic issues, and missed days of work and school due to bleeding. [22] [23] [24] [25] [26] Emicizumab (HEMLIBRA ® ; F. Hoffmann-La Roche, Basel, Switzerland) was developed to address the unmet needs of PwHA with inhibitors for effective, less burdensome prophylaxis.
Emicizumab is a humanized bispecific antibody that bridges activated factor IX and factor X, restoring the function of missing activated FVIII and haemostasis even in the presence of FVIII inhibitors.
High subcutaneous bioavailability 27 and a 4-to 5-week half-life 28 allow emicizumab to be administered subcutaneously once weekly.
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Emicizumab has been approved in several countries for prophylaxis to prevent or reduce bleeding frequency in adult and paediatric
PwHA with FVIII inhibitors.
In the HAVEN 1 Phase 3 clinical study of PwHA with inhibitors (NCT02622321), emicizumab prophylaxis was associated with statistically significant and clinically meaningful reductions in bleeding versus no prophylaxis. Annualized bleeding rate (95% confidence interval [CI]) for treated bleeds was 2.9 (1.7, 5.0) with emicizumab prophylaxis and 23.3 (12.3, 43.9) with no prophylaxis (episodic BPAs only); representing an 87% difference in favour of emicizumab prophylaxis (risk ratio: 0.13; P < 0.001). 29 Zero-treated bleeding events were experienced by 63% on emicizumab prophylaxis and 6% on no prophylaxis. In an intra-individual comparison among those previously using BPA prophylaxis in a prospective non-interventional study (NIS; NCT02476942), emicizumab prophylaxis resulted in a 79% decrease in bleeding rates (P < 0.001).
The purpose of the present paper is to provide a detailed description of HRQoL and health status outcomes in PwHA with inhibitors in HAVEN 1. PwHA (any severity) with inhibitors aged ≥12 years were enrolled if they had a history of high-titre FVIII inhibitors (≥5 BU/mL), had received BPAs to treat or control bleeding for ≥24 weeks before study entry and, in the previous 24 weeks, had ≥6 bleeds while on episodic BPAs or ≥2 bleeds while on prophylactic BPAs. emicizumab prophylaxis than no prophylaxis exceeded questionnaire-specific responder thresholds. Mean proportion of missed work days and number of days hospitalized were lower with emicizumab prophylaxis than no prophylaxis.
| MATERIAL S AND ME THODS

Conclusions:
In PwHA with inhibitors, emicizumab prophylaxis was associated with substantial and meaningful improvements in health-related outcomes.
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Participants on episodic BPA treatment before study entry Emicizumab prophylaxis was administered at 3.0 mg/kg weekly for 4 weeks followed by 1.5 mg/kg weekly. 
| Health status
Health status was assessed using the European Quality of Life 5-Dimensions 5-levels (EQ-5D-5L) questionnaire and visual analogue scale (EQ-VAS). 34, 35 The five dimensions of the EQ-5D-5L assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression; each with five levels of severity ranging from "no problems"
to "extreme problems". 35, 36 The five dimensions were combined into an index utility score (IUS) using the UK crosswalk value set; scores range from −0.594 (extreme problems on all dimensions) to 1 (no problems on all dimensions). 37 On the EQ-VAS, participants indicated their health status on a thermometer ranging from 0 (worst imaginable) to 100 (best imaginable). For both EQ-5D-5L and EQ-VAS, participants were asked to report the severity experienced on the day the questionnaire was completed.
| Work and school absences
Every 4 weeks, participants were asked to report how many days of work or school they missed during the previous 4 weeks due to haemophilia A, and how many days they should have been at work or school.
| Hospitalizations
Hospitalizations were recorded in the serious adverse events page of the electronic case report forms (eCRFs) by investigators. 
| Data collection and analysis
All outcomes, except for hospitalizations, were recorded by participants using an electronic, handheld device provided during the week 1 visit and before administration of study medication.
Participants were asked to record all HRQoL and health status outcomes every 4 weeks. In addition to scheduled assessments, they were asked to complete the EQ-5D-5L on any day during which bleeding occurred.
Demographic data, medical history and hospitalizations were collected from participants' medical records on an eCRF by clinicians. Analysis of covariance (model included treatment group, baseline score and the treatment-by-baseline interaction term as covariates) was used to compare the adjusted mean scores for Haem-A-QoL "Physical Health" and "Total" score and the EQ-5D-5L IUS and EQ-VAS between Arms A and B which were included as type 1 error-controlled secondary endpoints. The analysis of EQ-5D-5L IUS and EQ-VAS when a bleed occurred (unscheduled assessments) as compared with when no bleed occurred (monthly scheduled assessments) only included participants who had at least one scheduled and one unscheduled assessment.
Cumulative distribution function (CDF) plots of the change from baseline to week 25 in Haem-A-QoL "Physical Health" domain and "Total" scores were calculated for Arms A and B.
The proportion of participants achieving an improvement at week 25 larger than a previously published responder threshold was calculated for Haem-A-QoL "Total" score (−7), Haem-A-QoL "Physical
Health" score (−10), EQ-5D-5L IUS (+0.07) and EQ-VAS (+7).
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The rate of participant compliance with the completion of each questionnaire (Haem-A-QoL, Haemo-QoL SF and scheduled EQ-5L-5D) at each time point was calculated by dividing the number of questionnaires by the total number expected at that time.
All analyses were based on the data cut-off used for the primary analysis. 
| RE SULTS
| Study population
The participant population for the HAVEN 1 study has been described previously 29 and is summarized briefly here. Participants previously receiving episodic BPAs were randomized 2:1 to emicizumab prophylaxis (Arm A, n = 35) or no prophylaxis (Arm B, n = 18;
episodic BPAs only), and 49 participants previously receiving prophylactic BPAs received emicizumab prophylaxis in Arm C. Nearly all participants had severe haemophilia at diagnosis, and >50% in each treatment arm had experienced ≥9 bleeding events in the previous 24 weeks. Participants in Arm C were younger and had a higher rate of previous ITI than those in Arms A and B (Table 1) . 
| Compliance
Compliance with completion of all questionnaires across all time points was ≥90% for all outcome measures in all treatment arms.
| Haemophilia-specific Quality of Life in adults (Haem-A-QoL)
Baseline mean Haem-A-QoL "Total" and domain scores are listed in Table 2 . Emicizumab prophylaxis also produced notable improvements from baseline in other domains of the Haem-A-QoL (Table 3) , and improvements were qualitatively similar regardless of previous treatment regimen. There was no notable change in the no prophylaxis group (Arm B) in "Total" or domain scores at any time during the study.
| Haemophilia-specific Quality of Life in adolescents (Haemo-QoL SF)
The impact of emicizumab prophylaxis on Haemo-QoL SF is only presented for those participants previously treated with prophylactic BPAs (Arm C) because too few adolescents completed this questionnaire in Arms A (n = 3) and B (n = 2) for meaningful analysis.
At baseline, mean (95% CI) Haemo-QoL SF "Total" score was 30.7 (24.3, 37.2). Improvements from baseline with emicizumab prophylaxis were seen in most domains of the Haemo-QoL SF and in the "Total" score (Table 4) . Improvements were seen as early as week 5
and maintained through week 25.
| Health status
At baseline, mean (95% CI) EQ-VAS scores were 70.7 (63.6, 77. problem at baseline, and this may have limited the ability to detect an improvement in some items.
Haem-A-QoL domain
Previously on episodic BPAs Previously on prophylactic BPAs
Improvements in EQ-VAS and EQ-5D-5L IUS with emicizumab
prophylaxis were seen as early as week 5, maintained through week 25, and similar regardless of previous treatment regimen (Figure 4 ). In the no prophylaxis group (Arm B), EQ-VAS and EQ-5D-5L IUS scores remained near baseline levels or decreased slightly during the study. (Arms A and C) than in the no prophylaxis group (Arm B) achieved an improvement exceeding responder thresholds ( Figure S1C,D) . 39, 40 Mean EQ-VAS and EQ-5D-5L IUS scores were generally lower (worse) on days when bleeding occurred than on regularly scheduled reporting days ( Figure S2 ).
| Work/school absences and hospitalizations
The number of participants working before and during the study was 11 in the emicizumab prophylaxis group (Arm A) and 7 in the no prophylaxis group (Arm B). In the 4 weeks before study entry, the 
| D ISCUSS I ON
The results of this analysis demonstrate that participants receiving once weekly emicizumab prophylaxis in HAVEN 1 experienced statistically significant and clinically meaningful improvements in haemophilia-specific QoL and overall health status. On all measures, improvements were seen as early as week 5 and maintained through week 25. Moreover, improvements from baseline were similar regardless of whether previous BPA use was episodic or prophylactic. These improvements with emicizumab were likely due to a combination of substantial reductions in bleeding, the low rate of mostly mild adverse events and the once weekly subcutaneous dosing regimen.
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TA domain scores. Currently, there is no consensus on how changes in HRQoL outcomes should be interpreted, but the responder thresholds used in this study provide an estimate of notable improvements that, when combined with other findings, suggest meaningful improvements in participants' lives. 38 Further longitudinal assessments are needed, however, to quantify how the HRQoL changes observed with emicizumab prophylaxis correspond to real-life improvements.
In addition to improvements in HRQoL, emicizumab prophylaxis resulted in statistically significant improvements in overall health status as measured by the EQ-VAS and EQ-5D-5L IUS. As has been seen in other studies, 24, 42 EQ-5D-5L IUS scores were generally F I G U R E 4 Health status as measured by the European Quality of Life 5-Dimensions 5-levels (EQ-5D-5L) visual analogue scale (EQ-VAS) and index utility score (IUS). On the EQ-VAS, scores ranged from 0 (worst imaginable) to 100 (best imaginable). On the IUS, scores ranged from −0.594 (extreme problems on all dimensions) to 1 (no problems on all dimensions). BPA, bypassing agent; CI, confidence interval. A, Mean EQ-VAS over time. B, Mean EQ-5D-5L IUS over time worse on the days on which bleeding occurred than on regularly scheduled reporting days.
The strengths of this study include the use of psychometrically validated, haemophilia-specific and age-appropriate HRQoL instruments. 33, 43 The inclusion of overall health status measures that are not disease-specific provides a valuable complement to the disease-specific outcomes. The separate analyses for participants on different previous treatment regimens are also a strength, providing insights on how switching to emicizumab prophylaxis affected outcomes for participants with different treatment histories. This study was limited by the small number of adolescents in Arms A and B, making it difficult to evaluate the impact of emicizumab prophylaxis versus no prophylaxis on HRQoL and school attendance in this age group.
| CON CLUS IONS
This analysis of HAVEN 1 demonstrates that the substantial reductions in bleeding seen with emicizumab prophylaxis 29 were
accompanied by substantial and meaningful improvements in the daily lives of PwHA with inhibitors. Improvements in haemophiliaspecific QoL and overall health status were apparent as early as the first assessment after the start of treatment and maintained throughout the study. Importantly, improvements among participants previously treated with prophylactic BPAs mirrored the improvements seen in participants previously on episodic BPAs.
These findings suggest that emicizumab prophylaxis can help meet the needs of PwHA with inhibitors for effective, less burdensome prophylaxis.
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